Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.
about
Alzheimer's therapeutics: translation of preclinical science to clinical drug developmentFermented Sipjeondaebo-tang Alleviates Memory Deficits and Loss of Hippocampal Neurogenesis in Scopolamine-induced Amnesia in Mice.Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific RegionInappropriate drugs in elderly patients with severe cognitive impairment: results from the shelter studyThe anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicityCholinergic modulation of event-related oscillations (ERO).Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease.Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled TrialPositive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates.Clinicians' prescription preferences for treating patients with Alzheimer's disease in Shanghai.A Randomized, Crossover, Single-Dose Bioequivalence Study of Two Extended-Release Tablets of Donepezil 23 mg in Healthy Human Volunteers under Fasting and Fed States.Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment StrategyThe role of inflammatory processes in Alzheimer's disease.High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.Neural Differentiation of Human Pluripotent Stem Cells for Nontherapeutic Applications: Toxicology, Pharmacology, and In Vitro Disease Modeling.Long-Term Mangiferin Extract Treatment Improves Central Pathology and Cognitive Deficits in APP/PS1 Mice.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.Mango leaf extract improves central pathology and cognitive impairment in a type 2 diabetes mouse model.Nicotine effects on attentional reorienting in mid-age adults, and interactions with apolipoprotein E status.Intermittent Stimulation of the Nucleus Basalis of Meynert Improves Working Memory in Adult Monkeys.Sesamol supplementation prevents systemic inflammation-induced memory impairment and amyloidogenesis via inhibition of nuclear factor kappaB.Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
P2860
Q26829267-B4DC9526-B47B-48DD-8C7C-383EF0943D08Q27335037-44C7D60C-CD25-4573-BCD5-EF391156F62DQ28067006-3CE57D24-5DA2-4954-BEB2-6B57DCE8656CQ28484216-A6E4AC3B-1C07-42E5-AFE1-D88B909917F2Q28538399-8F5D61AF-C07C-4117-A256-74976FFBF1B1Q30413740-8D4BFF9C-C554-4462-BC72-21D4326061D8Q33754484-7D945424-A163-4A42-AE16-6F5093B36960Q34297733-15AF4237-4DE4-4657-BC16-CE7870A90993Q34762064-65B27FB7-8EA0-4796-AD8E-CFEFEF5F241AQ35606762-BB62048A-89AD-4839-841F-0088A115382FQ35663934-CE28A77E-7E0A-4636-84B2-C76A9B46DF6EQ36582006-950631CB-B70B-455E-BE28-E140048B1526Q36830837-CE5743E1-CAD9-4B84-B862-C1AA5E39DEF7Q37218956-42B8E1AD-6394-458C-AB45-B9D8EB7BCFFFQ37553489-E3E43CC4-4DD1-4634-AC37-C1740E2B0316Q38005630-F5880762-1D58-482D-90F8-E8949C73D67EQ38086651-7A6A622A-BAF3-44C2-9932-7DDF744B4070Q38531969-2DCC1974-7C3B-4141-9207-A7D37C4F7876Q38839191-027331E4-B6A9-4866-8DF3-C0546DD116F7Q38906350-F9410557-F03C-4470-8500-86C3D94AB5E3Q39478082-6BEF81F3-2E59-4D8D-83FD-59A06322A8FFQ46633828-E65492A6-3749-437D-88C0-C037595EDF77Q48147808-1892A467-4815-4E2D-BBB0-826BC4B36ED7Q48425285-49B10F20-8A36-4D71-8B17-56B40B031E9DQ53332226-C66702AB-317C-4E98-B4C3-7782F36F28BDQ57177786-AB2B910C-4F7E-4E87-8DCB-7DA43452467B
P2860
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Progressive cholinergic declin ...... rate to severe symptomatology.
@ast
Progressive cholinergic declin ...... rate to severe symptomatology.
@en
type
label
Progressive cholinergic declin ...... rate to severe symptomatology.
@ast
Progressive cholinergic declin ...... rate to severe symptomatology.
@en
prefLabel
Progressive cholinergic declin ...... rate to severe symptomatology.
@ast
Progressive cholinergic declin ...... rate to severe symptomatology.
@en
P2860
P921
P356
P1433
P1476
Progressive cholinergic declin ...... rate to severe symptomatology.
@en
P2093
Marwan Sabbagh
P2860
P2888
P356
10.1186/1471-2377-11-21
P5008
P577
2011-02-07T00:00:00Z
P5875
P6179
1000331125